According to a commentary, this Norwegian study is perhaps unique in its scale and length of follow-up; and though its findings might not lead to major BCG policy changes, it does stimulate further thought about existing practice and policies based on cost-effectiveness estimates, as well as underscoring the great need for a more effective future tuberculosis vaccine than BCG.